Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia

European Journal of Endocrinology

Volumn 168, Issue 5, 2013, Pages 665-674

  Bernard, Valérie ^a   Lombard Bohas, Catherine ^b   Taquet, Marie Caroline ^c   Caroli Bosc, François Xavier ^d   Ruszniewski, Philippe ^e   Niccoli, Patricia ^f   Guimbaud, Rosine ^g   Chougnet, Cécile N ^a   Goichot, Bernard ^c   Rohmer, Vincent ^d   Borson Chazot, Françoise ^h   Baudin, Eric ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e BEAUJON HOSPITAL   (France)

^f CNRS Marseille Universities   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOTOXIC AGENT; DACARBAZINE; DIAZOXIDE; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUCOSE; INTERFERON; OCTREOTIDE; OXALIPLATIN; STREPTOZOCIN; SUNITINIB;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BILE DUCT RUPTURE; BONE METASTASIS; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CUSHINGOID SYNDROME; CYTOLYSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FRANCE; GLUCOSE BLOOD LEVEL; HAND FOOT SYNDROME; HEART DISEASE; HEART FAILURE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INSULINOMA; LIVER METASTASIS; LIVER SURGERY; LUNG DISEASE; LUNG METASTASIS; LUNG SURGERY; LYMPH NODE METASTASIS; LYMPHOCYTOPENIA; MALE; METASTASIS; NAUSEA; NEUTROPENIA; ORTHOPEDIC SURGERY; PERIPHERAL EDEMA; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; TUMOR GROWTH; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; HYPOGLYCEMIA; INSULINOMA; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SIROLIMUS; TREATMENT OUTCOME;

EID: 84877120580     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-12-1101     Document Type: Article

References (43)

1. Soga J, Yakuwa Y & Osaka M. Insulinoma/hypoglycemic syndrome: a statistical evaluation of 1085 reported cases of a Japanese series. Journal of Experimental and Clinical Cancer Research 1998 17 379-388.
2. Placzkowski KA, Vella A, Thompson G.B., Grant CS, Reading CC, Charboneau JW, Andrews JC, Lloyd RV & Service FJ. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. Journal of Clinical Endocrinology and Metabolism 2009 94 1069-1073. (doi:10.1210/jc. 2008-2031)
3. Queiroz Almeida M., Machado MCC, Correa-Giannella ML. Giannella-Neto D & Albergaria Pereira MA. Endogenous hyperinsulinemic hypoglycemia: diagnostic strategies, predictive features of malignancy and long-term survival. Journal of Endocrinological Investigation 2006 29 679-687.
4. Lepage C, Ciccolallo L, De Angelis R, Bouvier AM, Faivre J & Gatta G. European disparities in malignant digestive endocrine tumours survival. International Journal of Cancer 2010 126 2928-2934.
5. Jensen RT, Cadiot G, Brandi M.L., De Herder WW, Kaltsas G, Komminoth P, Scoazec J-Y, Salazar R, Sauvanet A & Kianmanesh R. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012 95 98-119. (doi:10.1159/000335591)
6. Hay N & Sonenberg N. Upstream and downstream of mTOR. Genes and Development 2004 18 1926-1945. (doi:10.1101/gad. 1212704)
7. Missiaglia E, Dalai I, Barbi S., Beghelli S, Falconi M, Della Peruta M, Piemonti L, Capurso G, Di Florio A, Delle Fave G et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Journal of Clinical Oncology 2010 28 245-255. (doi:10.1200/JCO.2008.21.5988)
8. Yao JC, Shah MH, Ito T, Bohas C.L., Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J., De Vries EGE et al. Everolimus for advanced pancreatic neuroendocrine tumors. New England Journal of Medicine 2011 364 514-523. (doi:10.1056/ NEJMoa1009290)
9. Yao JC, Lombard-Bohas C, Baudin E., Kvols LK, Rougier P, Ruszniewski P, Hoosen S., St Peter J, Haas T, Lebwohl D et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. Journal of Clinical Oncology 2010 28 69-76. (doi:10.1200/JCO.2009.24.2669)
10. Sankhala K, Mita A, Kelly K., Mahalingam D, Giles F & Mita M. The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Targeted Oncology 2009 4 135-142. (doi:10.1007/s11523-009-0107-z)
11. Bourcier ME, Sherrod A, DiGuardo M & Vinik AI. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. Journal of Clinical Endocrinology and Metabolism 2009 94 3157-3162. (doi:10.1210/jc.2009-0788)
12. Atkins MB, Hidalgo M, Stadler W.M., Logan TF, Dutcher JP, Hudes GR, Park Y, Liou S-H, Marshall B. Boni JP et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology 2004 22 909-918. (doi:10.1200/JCO.2004.08.185)
13. Duran I, Siu LL, Oza A.M., Chung T-B, Sturgeon J, Townsley C.A., Pond GR, Seymour L & Niroumand M. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. European Journal of Cancer 2006 42 1875-1880. (doi:10.1016/j.ejca.2006. 03.015)
14. Hudes G, Carducci M, Tomczak P., Dutcher J, Figlin R, Kapoor A., Staroslawska E, Sosman J, McDermott D, Bodrogi I et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine 2007 356 2271-2281. (doi:10.1056/NEJMoa066838)
15. Aspinwall CA, Lakey JR & Kennedy RT. Insulin-stimulated insulin secretion in single pancreatic b cells. Journal of Biological Chemistry 1999 274 6360-6365. (doi:10.1074/jbc.274.10.6360)
16. Leibiger IB, Leibiger B, Moede T & Berggren PO. Exocytosis of insulin promotes insulin gene transcription via the insulin receptor/PI-3 kinase/p70 s6 kinase and CaM kinase pathways. Molecular Cell 1998 1 933-938. (doi:10.1016/S1097-2765 (00)80093-3)
17. Fuhrer DK, Kobayashi M & Jiang H. Insulin release and suppression by tacrolimus, rapamycin and cyclosporin A are through regulation of the ATP-sensitive potassium channel. Diabetes, Obesity & Metabolism 2001 3 393-402. (doi:10.1046/ j.1463-1326.2001.00150.x)
18. Di Paolo S., Teutonico A, Leogrande D., Capobianco C & Schena PF. Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes? Journal of the American Society of Nephrology 2006 17 2236-2244. (doi:10.1681/ASN.2006030196)
19. Fraenkel M, Ketzinel-Gilad M, Ariav Y., Pappo O, Karaca M, Castel J., Berthault M-F, Magnan C, Cerasi E, Kaiser N et al. mTOR inhibition by rapamycin prevents b-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008 57 945-957. (doi:10.2337/db07-0922)
20. Kulke MH, Bergsland EK & Yao JC. Glycemic control in patients with insulinoma treated with everolimus. New England Journal of Medicine 2009 360 195-197. (doi:10.1056/NEJMc0806740)
21. Ong GSY, Henley DE, Hurley D, Turner J.H., Claringbold PG & Fegan PG. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. European Journal of Endocrinology 2010 162 1001-1008. (doi:10.1530/EJE-09-1010)
22. Ferrer-García JC, Tolosa-Torréns M, Hernando-Meliá C, Arribas-Palomar L & Sánchez-Juan C. Everolimus resolving hypoglycemia, producing hyperglycemia, and necessitating insulin use in a patient with diabetes and nonresectable malignant insulinoma. Endocrine Practice 2011 17 e17-e20. (doi:10.4158/EP10282.CR)
23. Fiebrich H-B, Siemerink EJM, Brouwers AH, Links TP, Remkes W.S. Hospers GAP & De Vries EGE. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist 2011 16 783-787. (doi:10.1634/theoncologist.2010-0222)
24. Chandra P, Yarandi SS, Khazai N, Jacobs S & Umpierrez GE. Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma. American Journal of the Medical Sciences 2010 340 414-417. (doi:10.1097/MAJ.0b013e3181ee7be2)
25. Rindi G, Klimstra DS, Arnold R, Klöppel G, Bosman F.T., Komminoth P., et al Nomenclature and classification of neuroendocrine neoplasms of the digestive system. Lyon: IARC, 2010.
26. Rindi G, Klöppel G, Alhman H., Caplin M, Couvelard A, De Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal includinga grading system. Virchows Archiv 2006 449 395-401. (doi:10.1007/s00428-006-0250-1)
27. Therasse P, Arbuck SG, Eisenhauer E.A., Wanders J., Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC et al. New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000 92 205-216. (doi:10.1093/jnci/92.3.205)
28. Liu Y-J, Zhu G-P & Guan X.Y. Comparison of the NCI-CTCAE version 4.0 and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma. Oral Oncology 2012 48 554-559. (http://www.ncbi.nlm.nih.gov/pubmed/22289637)
29. Amar L, Baudin E, Burnichon N., Peyrard S, Silvera S, Bertherat J., Bertagna X, Schlumberger M, Jeunemaitre X, Gimenez-Roqueplo A-P et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. Journal of Clinical Endocrinology and Metabolism 2007 92 3822-3828. (doi:10.1210/jc.2007-0709)
30. Møller JE, Pellikka PA, Bernheim AM, Schaff HV, Rubin J & Connolly HM. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation 2005 112 3320-3327. (doi:10.1161/CIRCULATIONAHA.105. 553750)
31. Pavel M, Baudin E, Couvelard A., Krenning E, Öberg K, Steinmüller T, Anlauf M, Wiedenmann B & Salazar R. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendo-crinology 2012 95 157-176. (doi:10.1159/000335597)
32. Gill GV, Rauf O & MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgraduate Medical Journal 1997 73 640-641. (doi:10.1136/pgmj.73.864.640)
33. Goode PN, Farndon JR, Anderson J, Johnston ID & Morte JA. Diazoxide in the management of patients with insulinoma. World Journal of Surgery 1986 10 586-592. (doi:10.1007/ BF01655532)
34. Stehouwer CD, Lems WF, Fischer H.R., Hackeng WH & Naafs MA. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). Acta Endocrinologica 1989 121 34-40.
35. Gama R, Marks V, Wright J & Teale JD. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Clinical Endocrinology 1995 43 117-120; discussion 120-122. (doi:10.1111/j.1365-2265.1995.tb01901.x)
36. Healy ML, Dawson SJ, Murray RML, Zalcberg J & Jefford M. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma. Internal Medicine Journal 2007 37 406-409. (doi:10.1111/j.1445-5994.2007.01371.x)
37. De Herder W.W., Van Schaik E, Kwekkeboom D & Feelders RA. New therapeutic options for metastatic malignant insulinomas. Clinical Endocrinology 2011 75 277-284. (doi:10.1111/j.1365-2265. 2011.04145.x)
38. Gedaly R, Daily MF, Davenport D, McHugh P.P., Koch A, Angulo P & Hundley JC. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Archive Surgery 2011 146 953-958. (doi:10.1001/ archsurg.2011.186)
39. Agostino NM, Chinchilli VM, Lynch C.J., Koszyk-Szewczyk A, Gingrich R, Sivik J & Drabick JJ. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. Journal of Oncology Pharmacy Practice 2011 17 197-202. (doi:10.1177/1078155210378913)
40. Johnston O, Rose CL, Webster AC & Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. Journal of the American Society of Nephrology 2008 19 1411-1418. (doi:10.1681/ASN.2007111202)
41. Dunn C & Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs 2006 66 547-570. (doi:10.2165/ 00003495-200666040-00009)
42. Vahid B & Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008 133 528-538. (doi:10.1378/chest.07-0851)
43. Albiges L, Chamming's F, Duclos B, Stern M, Motzer RJ, Ravaud A & Camus P. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Annals of Oncology 2012 23 1943-1953. (doi:10.1093/annonc/mds115)